KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Operating Leases (2022 - 2025)

Ginkgo Bioworks Holdings filings provide 4 years of Operating Leases readings, the most recent being $417.1 million for Q4 2025.

  • On a quarterly basis, Operating Leases fell 4.94% to $417.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $417.1 million, a 4.94% decrease, with the full-year FY2025 number at $417.1 million, down 4.94% from a year prior.
  • Operating Leases hit $417.1 million in Q4 2025 for Ginkgo Bioworks Holdings, down from $422.9 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $452.3 million in Q2 2024 to a low of $221.8 million in Q4 2023.
  • Median Operating Leases over the past 4 years was $417.1 million (2025), compared with a mean of $394.5 million.
  • Biggest five-year swings in Operating Leases: crashed 46.32% in 2023 and later soared 97.79% in 2024.
  • Ginkgo Bioworks Holdings' Operating Leases stood at $413.3 million in 2022, then tumbled by 46.32% to $221.8 million in 2023, then surged by 97.79% to $438.8 million in 2024, then dropped by 4.94% to $417.1 million in 2025.
  • The last three reported values for Operating Leases were $417.1 million (Q4 2025), $422.9 million (Q3 2025), and $428.8 million (Q2 2025) per Business Quant data.